British American Tobacco: Clearing the Air - [Business Breakdowns, EP.162]

Episode Summary

Executive Summary: The episode traces British American Tobacco from its origins in the 1901 BAT/Imperial Tobacco joint venture to today’s mix of declining combustibles and fast-growing reduced-risk products. The core thesis is that BAT remains a highly cash-generative oligopoly with strong brands, stable margins, and a potentially underappreciated pathway to re-rating if nicotine pouches and other next-gen products scale.

Main Topics: BAT’s business mix and geography (Priority: 5/5): BAT is mainly a tobacco company with roughly half of revenue in the U.S., about a third in Europe, and the rest in Asia. Its legacy brands include Newport, Camel, Kent, Dunhill, Pall Mall, and Lucky Strike, plus a small but growing reduced-risk portfolio. Historical consolidation of the tobacco industry (Priority: 5/5): The discussion walks through tobacco’s long history, the Bonsack cigarette machine, American Tobacco’s monopoly, the creation of Imperial Tobacco and BAT, and the later consolidation of RJ Reynolds and Brown & Williamson into BAT’s U.S. business. Regulation as a structural moat (Priority: 5/5): Heavy advertising restrictions, taxation, and licensing rules make tobacco a difficult industry for entrants. These rules protect incumbents, limit marketing options, and reinforce brand power and scale advantages. Decline in combustibles and rise of reduced-risk products (Priority: 5/5): Traditional cigarette volumes continue to fall modestly, but pouches, vapes, and heated tobacco are offsetting some of the decline. The episode emphasizes Zyn/Velo-style nicotine pouches as a major long-term growth vector. Economics: margins, cash flow, and dividends (Priority: 4/5): BAT’s margins are exceptionally stable, capital intensity is low, and most operating cash flow converts to free cash flow. That supports debt reduction and a large dividend, making the stock look cheap on cash generation. Valuation, ESG, and re-rating potential (Priority: 4/5): BAT trades at a low multiple partly because of ESG-related investor exclusion and skepticism that tobacco is a ‘value trap.’ The guest argues this may change as investors accept that the business is no longer purely a melting ice cube. Key risks and optionality (Priority: 4/5): The main risk discussed is a U.S. menthol ban, which could materially hurt profits. Optionality comes from product approval, international expansion of Velo, and the possibility that nicotine use grows if reduced-risk products win share.

Key Arguments: BAT is not just a declining cigarette business; it has a meaningful and growing reduced-risk portfolio that could eventually replace a large share of revenue. The tobacco industry’s regulatory burden creates an oligopoly that protects incumbents and makes brand/scale advantages durable. Despite volume declines in cigarettes, pricing power and mix have historically kept revenues and margins stable. BAT’s cash conversion is so strong that its dividend and debt paydown can support attractive long-term returns even without rapid growth. Next-generation nicotine products may expand the total market rather than merely cannibalize cigarettes, especially if they are perceived as much less harmful. BAT’s valuation remains depressed partly because many institutional investors exclude tobacco on ESG grounds, which may not be permanent. A menthol cigarette ban in the U.S. is the clearest near-term downside risk, but the market may already be discounting much of it.

Data Points: Traditional tobacco revenue: ~£24 billion - BAT’s core combustibles business, mainly cigarettes, cigars, and chewing tobacco. Reduced-risk / new category revenue: ~£3 billion - Modern oral pouches, vaping, and heated tobacco products. BAT revenue mix by geography: ~45-50% U.S., ~1/3 Europe, remainder Asia - Approximate regional split discussed for the company. Gross margin: 78% in 2013; 83% in 2024 - Illustrates BAT’s unusually stable and high-margin profile. Operating margin: ~40% - Described as broadly stable for a long time. Operating cash flow: $9.2 billion last year - Cash generated by BAT in the prior year. Capital expenditures: $500 million last year - Shows very low capital intensity. Dividends paid: $5 billion last year - Large shareholder payout funded by strong cash flow. Dividend yield: ~10% - Based on roughly a $50 billion market cap. Debt after RJ Reynolds acquisition: ~$50 billion - Debt load taken on when BAT acquired the remainder of RJ Reynolds in 2017. 2023 U.S. cigarette volumes: down ~10% - A larger-than-usual decline in the U.S. combustible business. Historical U.S. volume declines: low single-digit declines annually - Typical volume erosion over the prior 5-10 years. Menthol exposure: ~40-50% of U.S. combustibles business - Why a menthol ban would be especially impactful for BAT. Potential profit impact of menthol ban: ~10-15% of profits, about $1 billion - Estimated downside if menthol cigarettes were banned in the U.S. BAT next-gen penetration: ~16-17% in 2023; likely >20% this year - Share of next-generation products, excluding Philip Morris being higher. Philip Morris next-gen penetration: ~30% and moving toward 40% - Described as the market leader in reduced-risk products. Japan next-gen mix: ~30% of revenues - Heated tobacco products have gained substantial share in Japan. Velo growth in Europe: 35% last year - BAT’s pouch brand growth, compared to Zyn’s momentum. BAT market cap: ~$50 billion - Used to illustrate the implied dividend yield. Tobacco settlement: $200 billion over 25 years - 1998 master settlement agreement with U.S. states.

Pivotal Quotes: "It took decades for most of the cigarette brands to kind of be developed. And so I think probably cannabis might be similar, but we'll see." — Evan Tyndall: On why BAT’s optionality in cannabis is unlikely to matter soon and why category development in nicotine took a long time. "The biggest lesson I've learned from kind of studying British American tobacco and investing in the company is to always look under the hood and make sure you really understand what's going on with the company." — Evan Tyndall: Closing lesson about deep diligence and avoiding surface-level narratives about value traps. "These tobacco companies, they're not melting ice cubes anymore because they have this business which is going to replace all of the traditional tobacco revenue that they're going to generate." — Evan Tyndall: Core investment thesis: reduced-risk products may offset combustibles decline and change the market’s perception.

Implications: BAT may be mispriced as a dying cigarette business when it is actually a high-cash-flow platform transitioning toward reduced-risk nicotine. Investors should watch product approval, menthol regulation, and pouch adoption as the main drivers of rerating.